Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 11:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 847 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topical Placebo Clear all
Completed Phase 2 Interventional Results available

Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab

NCT01867294
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Dermatologic Complication
Interventions
Doxycycline, Management of Therapy Complications, Placebo, Questionnaire Administration, Spironolactone, Sunscreen, Therapeutic Hydrocortisone
Drug · Procedure · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Urbana, Illinois • Des Moines, Iowa • Wichita, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 18, 2026, 11:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm

NCT00942851
View directory record Official record
Conditions
Focal Dystonia
Interventions
Acetyl-Hexapeptide Topical Treatment, placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Oct 18, 2026, 11:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

NCT00833495
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 18, 2026, 11:32 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

NCT03573401
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma
Interventions
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Fountain Valley, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 18, 2026, 11:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon

NCT00419419
View directory record Official record
Conditions
Raynaud's Disease, Scleroderma, Autoimmune Diseases
Interventions
Topical AmphiMatrix with nitroglycerin (MQX-503)
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
6
States / cities
Stanford, California • Farmington, Connecticut • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 18, 2026, 11:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine

NCT00276068
View directory record Official record
Conditions
Vulvar Disease
Interventions
topical lidocaine + oral desipramine, and/or placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2007 · Synced Oct 18, 2026, 11:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

NCT01289015
View directory record Official record
Conditions
Tinea Pedis
Interventions
NAFT-600 ( naftin 2 % gel ), Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
22
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 18, 2026, 11:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women

NCT02364882
View directory record Official record
Conditions
Female Sexual Health
Interventions
Sildenafil
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 18, 2026, 11:32 PM EDT
Completed Phase 1 Interventional

A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI

NCT02723539
View directory record Official record
Conditions
Diabetic Foot Infection
Interventions
MBN-101, Placebo
Drug
Lead sponsor
Microbion Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Fresno, California • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 18, 2026, 11:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain

NCT02324270
View directory record Official record
Conditions
Ankle Sprain
Interventions
Diclofenac epolamine, Placebo
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
658 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
31
States / cities
Birmingham, Alabama • Goodyear, Arizona • Carlsbad, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 18, 2026, 11:32 PM EDT
Completed Not applicable Interventional Results available

Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons

NCT00631566
View directory record Official record
Conditions
HIV Infections, Staphylococcal Infections
Interventions
Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
4
States / cities
San Diego, California • Bethesda, Maryland • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 18, 2026, 11:32 PM EDT
Terminated Phase 2 Interventional

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

NCT02728388
View directory record Official record
Conditions
NEUROFIBROMATOSIS 1
Interventions
aminolevulinic acid
Drug
Lead sponsor
Donald Basel
Other
Eligibility
14 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 18, 2026, 11:32 PM EDT
Completed Phase 2 Interventional

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

NCT03307577
View directory record Official record
Conditions
Acne Vulgaris
Interventions
UHE-101 Cream, Vehicle Cream
Drug · Other
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 18, 2026, 11:32 PM EDT
Not listed Phase 2 Interventional

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

NCT04759664
View directory record Official record
Conditions
EGFRI Induced Acneiform Lesions
Interventions
LUT014 Gel (Dose 1), LUT014 Gel (Dose 2), Placebo
Drug
Lead sponsor
Lutris Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Glendale, California • Santa Monica, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 18, 2026, 11:32 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

NCT03850483
View directory record Official record
Conditions
Psoriasis
Interventions
PF-06700841, Vehicle (Placebo)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
38
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 18, 2026, 11:32 PM EDT
Completed Phase 2 Interventional Results available

Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

NCT01270841
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Placebo, topical testosterone, Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
18
States / cities
Garden Grove, California • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 18, 2026, 11:32 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor

NCT05216770
View directory record Official record
Conditions
Laryngeal Dystonia, Spasmodic Dysphonia, Tremor
Interventions
Brain imaging, Laryngeal sensory block with topical bupivacaine
Other · Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 18, 2026, 11:32 PM EDT
Completed Phase 3 Interventional Results available

A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness

NCT02271854
View directory record Official record
Conditions
Muscle Soreness
Interventions
Diclofenac sodium gel 1%, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 35 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Oct 18, 2026, 11:32 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects

NCT01068158
View directory record Official record
Conditions
Head Lice
Interventions
0.5% Ivermectin Cream, Placebo control
Drug
Lead sponsor
Topaz Pharmaceuticals Inc
Industry
Eligibility
5 Months and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
7
States / cities
Little Rock, Arkansas • Delray Beach, Florida • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 18, 2026, 11:32 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

NCT00689078
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Acetate 1%, Prednisolone Acetate 0.12%, Loteprednol Etabonate 0.2%, Placebo
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 18, 2026, 11:32 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Effects of MRSA Bactericidal Gel To Promote Healing and Eliminate MRSA in cSSTI Vancogel(TM)

NCT00945152
View directory record Official record
Conditions
Bacterial Infections, Wounds
Interventions
Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R), Placebo, complex gel formulation without Vancomycin
Drug
Lead sponsor
Robert S Berman MD
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2024
U.S. locations
1
States / cities
Jupiter, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 18, 2026, 11:32 PM EDT
Completed Phase 4 Interventional

Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome

NCT01312402
View directory record Official record
Conditions
Infantile Nystagmus Syndrome
Interventions
topical brinzolamide 1% in 5mL ophthalmic medication, Placebo in 5 mL dispenser
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 18, 2026, 11:32 PM EDT
Completed Phase 2 Interventional Results available

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

NCT03216902
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution, Topical medium dose of DE-126 Ophthalmic Solution, Topical high dose of DE-126 Ophthalmic Solution, 0.005% Latanoprost Ophthalmic Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Artesia, California • Mission Hills, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 18, 2026, 11:32 PM EDT
Terminated Phase 3 Interventional

Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)

NCT02074007
View directory record Official record
Conditions
Acute Otitis Media
Interventions
AR01, Placebo Comparator
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
2 Months to 18 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
21
States / cities
Phoenix, Arizona • Bakersfield, California • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 18, 2026, 11:32 PM EDT